Asarfi Hospital Limited · BSE:ASARFI
Asarfi Hospital — Q3 FY26 Earnings Presentation
22 slides from Asarfi Hospital's earnings presentation, Feb 9, 2026
Slide 1: Submission of Investor Presentation to BSE
असफ हॉ ीटल सबके िलए ा AHL/AO/2026/1095 Date: 09.02.2026 To The BSE Limited Listing Department 25th Floor, Phiroze Jeejeebhoy Tower Dalal Street Mumbai – 400 001 Sub: Submission of Investor Presentation. Ref: Scrip Code: 543943 Dear Sir/Ma’am, Pursuant to Regulation 30 of the SEBI (Listing Obligation
Slide 2: Investor Presentation Q3'FY26
“Leading Healthcare Provider in Eastern India” Investor Presentation Q3’FY26 1
Slide 3: Agenda
1 Company Overview Agenda 2 Journey Over The Years 3 Infrastructure and Facilities 4 Leadership Team 5 Financial & Operational Performance 2
Slide 4: Asarfi Hospital: At a Glance
Asarfi Hospital: At a Glance Healthcare Excellence Since 2005 Serving Dhanbad and neighboring areas for 20 years with affordable, best-in-class healthcare facilities. Operating two hospitals with 330 total beds across Super-Specialty and Cancer Care Units. The Super-Specialty hospital is the fir
Slide 5: Journey Over The Years
Journey Over The Years 2005 2008 2016 2017 2022 2023 2024 2025 Incorporation IPD Dept Expansion Expansion Cancer hospital IPO Cancer hospital Strategic Phase 1 Phase 2 construction operationalised partnership 2005-2009: Foundation 2016-2022: Expansion 2023-2025: Cancer Hospital, IPO and Partnerships
Slide 6: Our Departments
Our Departments Paediatrics & Obstetrics & Cardiology Neurosciences General medicine General Surgery Neonatology Gynaecology Gastroenterology Orthopaedics Burn & Plastic Surgery Oncology Nephrology Urology Ophthalmology ENT Day Care Dental Sciences Physiotherapy Emergency services Nutrition & Dietet
Slide 7: Infrastructure and Facilities
Infrastructure and Facilities Asarfi Hospital, Dhanbad Asarfi Cancer Institute, Dhanbad Varian True Beam 265 Beds | ₹24,293 ARPOB | 65 Beds | ₹43,240 ARPOB | Jharkhand’s 1st & Most 61% Occupancy | ALOS 4.3 Days 37% Occupancy | ALOS 4.6 Days Advanced Radiation Machine Established in 2005 Establis
Slide 8: Leadership Team
Leadership Team Harendra Singh Udai Pratap Singh Sukanti Kumar Das Promoter & CFO Promoter & MD Non-Executive Director • A visionary entrepreneur inspired by • Started his career in 2017, he is a • Renowned Consultant Gynaecologist the Company’s Purpose—Health for All. process and system driven pers
Slide 9: Redefining Healthcare
Redefining Healthcare Robust financial performance with 23% Revenue CAGR in last 3 years, 43% YoY Revenue 0`` Growth in FY25, 20% EBITDA Margins, 9% PAT Margins and 14% ROCE as of FY25. In Q3’FY26, Revenue grew by 40% with 22% EBITDA Margins and 12% PAT Margins. Asarfi Hospital is proudly serving th
Slide 10: Strengthening Core Clinical Capabilities for Long-Term Value
Strengthening Core Clinical Capabilities for Long-Term Value Redefining Nuclear Medicine Diagnostics and Therapeutics Enhancing Invasive and Interventional Cardiology Capabilities • Investment in GE Healthcare’s Dual-Detector SPECT Gamma • Upgrading existing Cath Lab with the Philips Azurion 5 M12 I
Slide 11: Financial and Operational Performance
Financial and Operational Performance 10
Slide 12: Key Highlights – Q3'FY26
Key Highlights – Q3’FY26 Financials (Standalone): IPD-OPD Revenues (₹ in lakhs): Revenue Growth YoY EBITDA Margin 3,817 42% 40% 22% YoY Growth in IPD Revenues to ₹46 Cr in Q3’FY26 in Q3’FY26 2,679 (vs ₹33 Cr in Q3’FY25) (vs 21% in Q3’FY25) 505 695 37% EBIT Margin PAT Margin YoY Growth in OPD Revenue
Slide 13: Financial Highlights - Standalone
Financial Highlights - Standalone Revenue (₹ in Lakhs) EBITDA (₹ in Lakhs) and Margin % 12,000 3,000 21% 21% 10,000 2,500 21% 22% 20% 8,000 2,000 6,000 1,500 4,000 12,657 4,485 1,000 4,606 8,667 1,012 1,860 2,606 3,289 891 2,000 500 698 - - Q3'FY25 Q2'FY26 Q3'FY26 9M'FY25 9M'FY26 Q3'FY25 Q2'FY26 Q3'
Slide 14: Financial Highlights - Consolidated
Financial Highlights - Consolidated Revenue (₹ in Lakhs) EBITDA (₹ in Lakhs) and Margin % 12,000 21% 20% 3,000 10,000 2,500 21% 22% 20% 8,000 2,000 6,000 1,500 4,000 12,667 1,000 8,667 4,489 4,610 1,011 1,847 2,597 3,289 887 2,000 500 695 - - Q3'FY25 Q2'FY26 Q3'FY26 9M'FY25 9M'FY26 Q3'FY25 Q2'FY26 Q
Slide 15: Revenue Mix – Q3'FY25 vs Q3'FY26 (Super-Specialty)
Revenue Mix – Q3’FY25 vs Q3’FY26 Super-Specialty Hospital Unit Q3’FY26 YoY Revenue Growth % by Specialty Cardiology 15.1% Cardiology General Medicine -4.5% 14% General Medicine 23% Neurosciences 76.8% 6% Neurosciences General Surgery 0.4% General Surgery 5% Paediatrics and Neonatology 48.2% Q3’FY26
Slide 16: Revenue Mix – Q3'FY25 vs Q3'FY26 (Cancer Hospital)
Revenue Mix – Q3’FY25 vs Q3’FY26 Cancer Hospital Unit Q3’FY26 YoY Revenue Growth % by Specialty Medical Oncology 58% 18% Medical Oncology Surgical Oncology Surgical Oncology -2% 15% Q3’FY26 54% Radiation Oncology 14% Others* Radiation Oncology 74% 3% Revenue Contribution by 14% Top 3 Specialties Gro
Slide 17: IPD-OPD Highlights (Both Hospital Units)
IPD-OPD Highlights (Both Hospital Units) IPD-OPD Volumes IPD-OPD Revenues (₹ in Lakhs) 140,000 12,000 124,034 10,587 120,000 10,000 100,000 83,605 8,000 6,947 80,000 6,000 60,000 51,717 3,773 3,817 39,331 4,000 40,000 29,292 2,679 1,563 1,854 20,000 16,284 2,000 8,414 9,303 505 637 695 3,324 3,923 0
Slide 18: Super-Specialty Hospital Unit: ARPOB, Beds and Occupancy
Unit-wise ARPOB, Bed Capacity and Occupancy % Super-Specialty Hospital Unit ARPOB Bed Capacity and Occupancy % 30,000 64% 64% 60% 24,293 61% 56% 21,876 20,247 21,659 300 18,659 20,000 200 Key factors contributing to the 10,000 100 250 265 265 250 265 increase in ARPOB in Super- 0 0 Specialty Unit (Q
Slide 19: Surgery Count
Surgery Count Surgery Count 6000 5000 178 187 187 212 370 4000 533 124 128 523 107 3000 145 284 417 1405 2000 62 52 62 502 53 81 144 67 64 190 138 63 681 21 201 185 1000 37 45 168 59 546 444 1465 106 149 1014 198 111 488 503 0 113 Q3'FY25 Q2'FY26 Q3'FY26 9M'FY25 9M'FY26 Cardiology Gastroenterology G
Slide 20: Profit and Loss Account (Standalone)
Profit and Loss Account (Standalone) (₹ in Lakhs) Particulars Q3'FY25 Q2'FY26 Q3'FY26 QoQ % YoY% 9M'FY25 9M'FY26 YoY% Revenue from operations 3,289 4,485 4,606 3% 40% 8,667 12,657 46% Material costs (718) (1,059) (977) -8% 36% (2,036) (2,893) 42% Employee benefit expenses (452) (610) (748) 23% 65% (
Slide 21: Profit and Loss Account (Consolidated)
Profit and Loss Account (Consolidated) (₹ in Lakhs) Particulars Q3'FY25 Q2'FY26 Q3'FY26 QoQ % YoY% 9M'FY25 9M'FY26 YoY% Revenue from operations 3,289 4,489 4,610 3% 40% 8,667 12,667 46% Material costs (718) (1,059) (977) -8% 36% (2,036) (2,893) 42% Employee benefit expenses (453) (612) (749) 22% 65%
Slide 22: Disclosure and Contact Details
Disclosure and Contact Details Certain matters discussed in this presentation may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements do not guarantee future performanc